Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: A case-control study of histological factors and alterations in oncogene expression

International Journal of Radiation Oncology Biology Physics

Volumn 45, Issue 1, 1999, Pages 73-83

  Elkhuizen, Paula H M ^a   Voogd, Adri C ^b   Van Den Broek, Lambert C J M ^a   Tan, Iris T C ^a   Van Houwelingen, Hans C ^a   Leer, Jan Willem H ^a   Van De Vijver, Marc J ^a,c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Eindhoven   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Breast neoplasm; Breast conserving therapy; Local recurrence; Oncogene; Risk factors

Indexed keywords

CD31 ANTIGEN; CYCLIN D1; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; NEU DIFFERENTIATION FACTOR; PROTEIN BCL 2; PROTEIN P53; UVOMORULIN;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER RECURRENCE; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE NEU; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR;

ADULT; AGE DISTRIBUTION; AGED; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; REGRESSION ANALYSIS; RISK FACTORS;

EID: 0032814230     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00158-3     Document Type: Article

References (83)

1. Borger J., Kemperman H., Hart A., et al. Risk factors in breast-conservation therapy. J Clin Oncol. 12:1994;653-660.
2. Gage I., Recht A., Gelman R., et al. Long-term outcome following breast-conserving surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 33:1995;245-251.
3. Fourquet A., Campana F., Zafrani B., et al. Prognostic factors of breast recurrence in the conservative management of early breast cancer A 25-year follow-up . Int J Radiat Oncol Biol Phys. 17:1989;719-725.
4. Lichter A.S., Lippman M.E., Danforth D.N., et al. Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast A randomized trial at the National Cancer Institute . J Clin Oncol. 10:1992;976-983.
5. van Dongen J.A., Bartelink H., Lerut T., et al. Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial. J Natl Cancer Inst Monogr. 11:1992;15-18.
6. Solin L.J., Fowble B.L., Martz K.L., et al. Definitive irradiation for early stage breast cancer: The University of Pennsylvania experience. Int J Radiat Oncol Biol Phys. 14:1988;235-242.
7. Fowble B.L., Solin L.J., Schultz D.J., et al. Breast recurrence following conservative surgery and radatiation Patterns of failure prognosis and pathologic findings from mastectomy specimens with implications for treatment . Int J Radiat Oncol Biol Phys. 19:1990;833-842.
8. Fisher B., Bauer M., Margolese R. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 312:1985;665-673.
9. Elkhuizen P.H.M., van de Vijver M.J., Hermans J., et al. Local recurrence after breast conserving treatment High incidence in young patients and association with poor survival . Int J Radiat Oncol Biol Phys. 40:1998;859-867.
10. Fisher B., Redmond C., Poisson R., et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 320:1989;822-828.
11. Veronesi U., Saccozzi R., Del Vecchio M., et al. Comparing radical mastectomy with quadrantectomy axillary dissection and radiotherapy in patients with small cancers of the breast. N Engl J Med. 305:1981;6-11.
12. Clarke D.H., Le M.G., Sarrazin D., et al. Analysis of local-regional relapses in patients with early breast cancers treated by excision and radiotherapy Experience of the Institut Gustave-Roussy . Int J Radiat Oncol Biol Phys. 11:1985;137-145.
13. Clark R.M., Wilkinson R.H., Mahoney L.J., et al. Breast cancer A 21 year experience with conservative surgery and radiation . Int J Radiat Oncol Biol Phys. 8:1982;967-975.
14. Chauvet B., Reynaud-Bougnoux A., Calais G., et al. Prognostic significance of breast relapse after conservative treatment in node-negative early breast cancer. Int J Radiat Oncol Biol Phys. 19:1990;1125-1130.
15. Fisher B., Anderson S., Fisher E.R., et al. Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet. 338:1991;327-331.
16. Veronesi U., Marubini E., DelVecchio M., et al. Local recurrences and distant metastases after conservative breast cancer treatments Partly independent events . J Natl Cancer Inst. 87:1995;19-27.
17. Kemperman H., Borger J., Hart A., et al. Prognostic factors for survival after breast conserving therapy for stage I and II breast cancer. The role of local recurrence. Eur J Cancer. 31A:1995;690-698.
18. Whelan T., Clark R., Roberts R., et al. Ipsilateral breast tumor recurrence postlumpectomy is predictive of subsequent mortality Result from a randomized trial . Int J Radiat Oncol Biol Phys. 30:1994;11-16.
19. Haffty B.G., Reiss M., Beinfield M., et al. Ipsilateral breast tumor recurrence as a predictor of distant disease Implications for systemic therapy at the time of local relapse . J Clin Oncol. 14:1996;52-57.
20. Schnitt S.J., Abner A., Gelman R., et al. The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy. Cancer. 74:1994;1746-1751.
21. Locker A.P., Ellis I.O., Morgan D.A.L., et al. Factors influencing local recurrence after excision and radiotherapy for primary breast cancer. Br J Surg. 76:1987;890-894.
22. Vicini F.A., Recht A., Abner A., et al. Recurrence in the breast following conservative surgery and radiation therapy for early-stage breast cancer. J Natl Cancer Inst Monogr. 11:1992;33-39.
23. Veronesi U., Volterrani F., Luini A., et al. Quadrantectomy versus lumpectomy for small size breast cancer. Eur J Cancer. 26:1990;671-673.
24. Fisher E.R., Anderson S., Redmond C., et al. Ipsilateral breast tumor recurrence and survival following lumpectomy and irradiation Pathological findings from NSABP protocol B-06 . Semin Surg Oncol. 8:1992;161-166.
25. Fisher E.R., Costantino J., Fisher B., et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) protocol B-17. Cancer. 75:1995;1310-1319.
26. Kurtz J.M., Spitalier J.-M., Amalric R., et al. Mammary recurrences in women younger than forty. Int J Radiat Oncol Biol Phys. 15:1988;271-276.
27. Veronesi U., Salvadori B., Luini A., et al. Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomised trials on 1973 patients. Eur J Cancer. 31A:1995;1574-1579.
28. de la Rochefordiere A., Asselain B., Campana F. Age as a prognostic factor in premenopausal breast carcinoma. Lancet. 341:1993;1039-1043.
29. Sismondi P., Bordon R., Arisio R., et al. Local recurrences after breast conserving surgery and radiotherapy Correlation of histopathological risk factors with age . Breast. 3:1994;8-13.
30. Kurtz J.M., Jacquemier J., Almaric R. Why are local recurrences after breast-conserving therapy more frequent in younger patients. J Clin Oncol. 8:1990;591-598.
31. Silvestrini R., Veneroni S., Daidone M.G., et al. The bcl-2 protein A prognostic indicator strongly related to p53 protein in lymphnode negative breast cancer patients . J Natl Cancer Inst. 86:1994;499-504.
32. Richards M.A., Smith P., Fentiman I.S., et al. Age as prognostic factor in premenopausal breast cancer. Lancet. 341:1993;1484-1485.
33. Lowe S.W., Bodis S., McClatchey A., et al. p53 status and the efficacy of cancer therapy in vivo. Science. 266:1994;807-810.
34. O'Connor P.M., Jackman J., Jondle D. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res. 53:1993;4776-4780.
35. van de Vijver M.J., Peterse J.L., Mooi W.J., et al. Neu-protein overexpression in breast cancer. N Engl J Med. 319:1988;1239-1245.
36. Ramachandra S., Machin L., Ashley S., et al. Immunohistochemical distribution of c-erbB-2 in situ breast carcinoma - a detailed morphological analysis. J Pathol. 161:1990;7-14.
37. Borgan O., Langholz B. Nonparametric estimation of relative mortality from nested case-control studies. Biometrics. 49:1993;593-602.
38. Elston C.W., Ellis I.O. Pathologic prognostic factors in breast cancer. The value of histological grade in breast cancer Experience from a large study with long-term follow-up . Histopathology. 19:1991;403-410.
39. Holland R., Peterse J.L., Millis R.R., et al. Ductal carcinoma in situ A proposal for a new classification . Semin Diagn Pathol. 11:1994;167-180.
40. Berg F.M., Baas I.O., Polak M.M., et al. Detection of p53 overexpression in routinely paraffin-embedded tissue of human carcinoma using a novel target unmasking fluid. Am J Pathol. 142:1993;381-385.
41. Veronese S.M., Gambacorta M., Gottardi O. Proliferation index as a prognostic marker in breast cancer. Cancer. 71:1993;3926-3931.
42. Bouzubar N., Walker K.J., Griffiths K. Ki67 immunostaining in primary breast cancer Pathological and clinical associations . Br J Cancer. 59:1989;943-947.
43. Weidner N., Semple J.P., Welch W.R., et al. Tumor angiogenesis and metastases-correlation in invasive breast carcinoma. N Engl J Med. 324:1991;1-8.
44. Breslow N.E., Day N.E. Statistical methods in cancer research The analysis of case-control studies . 1980;IARC Scientific Publications.
45. Stotter A.T., McNeese M.D., Ames F.C., et al. Predicting the rate and extent of locoregional failure after breast conservation therapy for early breast cancer. Cancer. 64:1989;2217-2225.
46. Spitalier J.-M., Gambarelli J., Brandone H., et al. Breast-conserving surgery with radiation therapy for operable mammary carcinoma A 25-year experience . World J Surg. 10:1986;1014-1020.
47. Schnitt S.J., Connolly J.L., Recht A., et al. Influence of infiltrating lobular histology on local tumor control in breast cancer patients treated with conservative surgery and radiotherapy. Cancer. 64:1989;448-454.
48. Kurtz J.M., Jacquemier J., Torhorst J., et al. Conservation therapy for breast cancers other than infiltrating ductal carcinoma. Cancer. 63:1989;1630-1635.
49. Weiss M.C., Fowble B.L., Solin L.J., et al. Outcome of conservative therapy for invasive breast cancer by histologic subtype. Int J Radiat Oncol Biol Phys. 23:1992;941-947.
50. Sastre-Garau X., Jouve M., Asselain B., et al. Infiltrating lobular carcinoma of the breast. Cancer. 77:1996;113-120.
51. Fisher B., Anderson S. Conservative surgery for the management of invasive an noninvasive carcinoma of the breast NSABP trials . World J Surg. 8:1994;63-69.
52. Berx G., Cleton-Jansen A., Nollet F., et al. E-cadherin is a tumor/invasion suppressor gene mutated in human lobular breast cancers. EMBO J. 14:1995;6107-6115.
53. Moll R., Mitze M., Frixen U.H., et al. Differential loss of of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol. 143:1993;1731-1742.
54. Lindley R., Bulman A., Parsons P., et al. Histologic features predictive of an increased risk of early local recurrence after treatment of breast cancer by local tumor excision and radical radiotherapy. Surgery. 105:1987;13-20.
55. Kurtz J.M., Jacquemier J., Amalric R., et al. Risk factors for breast recurrence in premenopausal and postmenopausal patients with ductal cancers treated by conservation therapy. Cancer. 65:1990;1867-1878.
56. Lipponen P., Ji H., Aaltomaa P., et al. P53 protein expression in breast cancer is related to histopathological characteristics and prognosis. Int J Cancer. 55:1993;51-56.
57. Lowe S.W. Cancer therapy and p53. Curr Opin Oncol. 7:1995;547-553.
58. Jansson T., Inganäs M., Sjögren S., et al. p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy A novel hypothesis based on clinical findings . J Clin Oncol. 13:1995;2745-2751.
59. Reed J.C. Bcl-2 and the regulation of programmed cell death. J Cell Biol. 124:1994;1-6.
60. Joensuu H., Pylkkanen L., Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Clin Pathol. 145:1994;1191-1198.
61. Gillett C., Fantl V., Smith R., et al. Amplification and overexpressing of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 54:1994;1812-1817.
62. McIntosh G.G., Anderson J.J., Milton I., et al. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene. 11:1995;885-891.
63. Zhang Y., Caamano J., Cooper F., et al. Immunohistochemistry of cyclin D1 in human breast cancer. Am J Clin Pathol. 102:1994;695-698.
64. Schuuring E., Verhoeven E., van Tinteren H., et al. Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patient with operable breast cancer. Cancer Res. 52:1992;5229-5234.
65. Peters G., Fantl V., Smith R., et al. Chromosome 11q13 markers and D-type cyclins in breast cancer. Breast Cancer Res Treat. 33:1995;125-135.
66. Jacquemier J., Kurtz J.M., Amalric R., et al. An assessment of extensive intraductal component as a risk factor for local recurrence after breast-conserving therapy. Br J Cancer. 61:1990;873-876.
67. Bartelink H., Borger J., van Dongen J.A., et al. The impact of tumor size and histology on local control after breast conserving therapy. Radiother Oncol. 11:1988;297-303.
68. Holland R., Veling S.H.J., Mravunac M., et al. Histologic multifocality of Tis T1-2 carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer. 56:1985;979-990.
69. Holland R., Connolly J.L., Gelman R., et al. The presence of an extensive intraductal component following a limited excision correlates with prominent residual disease in the remainder of the breast. J Clin Oncol. 8:1990;113-118.
70. Silverstein M.J., Barth A., Poller D.N. Ten year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur J Cancer. 31:1995;1425-1427.
71. Hiramatsu H., Bornstein B.A., Recht A., et al. Local recurrence after conservative surgery and radiation therapy for ductal carcinoma in situ. Cancer J Sci Am. 1:1997;55-61.
72. Solin L.J., McCormick B., Recht A., et al. Mammography detected clinically occult ductal carcinoma in situ (intraductal carcinoma) treated with breast-conserving surgery and definitive breast irradiation. Cancer J Sci Am. 2:1996;158-165.
73. Bartelink H., Rubens R.D., van der Schueren E., et al. Hormonal therapy prolongs survival in irradiated locally advanced breast cancer A European Organization for Research and Treatment of Cancer randomized phase III . J Clin Oncol. 15:1997;207-215.
74. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer Correlation of relapse and survival with amplification of the HER-2/neu oncogene . Science. 235:1987;177-182.
75. O'Reilly S.M., Barnes D.M., Camplejohn R.S., et al. The relationship between c-erbB-2 expression S-phase fraction and prognosis in breast cancer. Br J Cancer. 63:1991;444-446.
76. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
77. Allred D.C., Clark G.M., Molina R., et al. Overexpression of HER-2/neu and its relation with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 23:1992;974-979.
78. Pierce L.J., Merino M.J., d'Angelo T., et al. Is c-erb B2 a predictor for recurrent disease in early stage breast cancer? Int J Radiat Oncol Biol Phys. 28:1993;395-403.
79. Stal O., Sullivan S., Wingren S., et al. C-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer. 31A:1995;2185-2190.
80. Haffty B.G., Brown F., Carter D., et al. Evaluations of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer A case-control study . Int J Radiat Oncol Biol Phys. 35:1996;751-757.
81. Gusterson B.A., Gelber R.D., Goldhirsch A., et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol. 10:1992;1049-1056.
82. Cohen P., Zakris E., Shih L.-S., et al. HER 2/neu oncogene expression in invasive breast cancers with and without an extensive intraductal component. Lab Invest. 68:1993;14A.
83. Fowble B.L., Schultz D.J., Overmoyer B., et al. The influence of young age on outcome in early breast cancer. Int J Radiat Oncol Biol Phys. 30:1994;23-33.